Bayer: extends research into breast cancer

(CercleFinance.com) - Bayer has today announced that it is going to expand its clinical development programme, concentrating on vasomotor symptoms (VMS) caused by hormone therapy taken by some women with breast cancer, through the launch of a phase-III trial, dubbed OASIS 4.


The majority of these patients with hormone receptor positive breast cancer receive adjuvant hormone treatment. Vasomotor symptoms (VMS), also known as “hot flashes” are a known undesirable effect of hormone therapy.

“Vasomotor symptoms can intensively affect their quality of life and treatment continuation, which in turn might impact the effectiveness of their cancer therapy and hence their survival,” said Dr Christian Rommel, member of the Executive Committee of Bayer AG's Pharmaceutical Division and Global Head of Research and Development.

“By adding OASIS 4 to our Phase III programme with elinzanetant, we aim to help patients experiencing vasomotor symptoms caused by their endocrine therapy, to increase their quality of life,” Dr Rommel adds.

Copyright (c) 2022 CercleFinance.com. All rights reserved.